CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 70 enrolled
Drug / intervention
Olanzapine +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02643355
NCT02643355N/ACompleted

Utility of Olanzapine in the Treatment of Opioid Withdrawal in the Emergency Department

Hennepin Healthcare Research Institute·interventional·Posted Dec 31, 2015·Updated Jul 10, 2019

In Brief

A clinical study evaluating Olanzapine and Clonidine for Substance Withdrawal Syndrome. Completed, enrolled 70 participants across 1 site.

Detailed Summary

Withdrawal from opioids is a clinical scenario that emergency department physicians encounter frequently. Patients who present with opioid withdrawal display symptoms such as agitation, anxiety, myalgias, abdominal pain, diarrhea, nausea, and vomiting. Currently, the standard treatment for opioid withdrawal is clonidine (an alpha-2 adrenergic agonist), as well as supportive cares (anti-emetics, intravenous fluids). Olanzapine is an atypical antipsychotic that is given frequently in the ED for many of the same symptoms that are seen in patients who are experiencing opioid withdrawal, however its use in this toxidrome has never been studied. The hypothesis of this study is that olanzapine is a safe and efficacious option when compared to clonidine for the treatment of opioid withdrawal in the emergency department.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
20162017201820192020202120222023202420252026
First PostedDec 31, 2015
Enrollment StartNov 1, 2015
Primary CompletionJun 21, 2017
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 10.5 years ago

Interventions

Olanzapinedrug

Clonidinedrug